Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Clin Cancer Res. 2018 Sep 26;25(1):346–357. doi: 10.1158/1078-0432.CCR-18-1129

Figure 3. DISARM identifies common candidates for cisplatin-resistant SCLC and LUAD.

Figure 3.

(A-B) Maps illustrating common and unique drugs (A) and drug targets (B) selected as top candidates by DISARM for SCLC and LUAD using IC50 data from GDSC. (C) Examples of DISARM-generated 2×2 plots for obatoclax, selected by DISARM for both cisplatin-resistant SCLC and LUAD. IC50 values are reported as μM. (D) Venn diagram illustrating numbers of unique and common mRNA-based predictive biomarkers of obatoclax sensitivity between SCLC and LUAD, including increased expression of the transcription factor ASCL1 (See also Table S5).